### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	Responses)																	
1. Name and Address of Reporting Person * SNYDER STEPHEN ANDREW				2. Issuer Name and Ticker or Trading Symbol MEDICAL TRANSCRIPTION BILLING, CORP [MTBC]							CORP	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director						
(Last) (First) (Middle) 7 CLYDE ROAD				3. Date of Earliest Transaction (Month/Day/Year) 04/04/2015											President			
(Street) SOMERSET, NJ 08873				4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City)		(State)	(Zip)			Т	able I - N	on-I	Derivat	ive Sec	uritie	es Acquire	d, Disposed	of, or Bene	eficially Ow	ned		
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)		n Dat	ate, if	3. Transa Code (Instr. 8)	(A) or Disposed		of (D) Owned Foll		\ /			of l Be	7. Nature of Indirect Beneficial Ownership			
				(Month/Day/		carj	Code	١	V Am		(A) or (D)		(msu. 3 and 4)			or Indirect (I) (Instr. 4)		
Common s	stock		04/04/2015				M		33,	333 A	4	\$ 0 (1) 3	3,333			D		
Common s	Common stock 04/04/2015		04/04/2015			F <sup>(2)</sup>		8,3	33 I	)	\$ 2.11 2	5,000			D			
Series A Cumulative Redeemable Perpetual Preferred Stock  11/04/2015		11/04/2015			P <sup>(3)</sup>		800	) <i>A</i>	4	\$ 25 8	00			D				
Reminder: Re	eport on a se	parate line for each	class of securities l				•	Pers con form	sons v itained n disp	l in thi lays a	s for	m are not ently vali	required d OMB co	of informa to respond ntrol numb	d unless th		C 147	4 (9-02)
			Table II -	erivative (e.g., puts,									wnea					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion   Date   Exercise   (Month/Day/Year)   rice of   erivative	3A. Deemed Execution Date, i) any (Month/Day/Yea	Code	ransaction of Dode Securinstr. 8) Acquired or D of (E		urities uired (A) isposed D) r. 3, 4,	(Month/Day/Y			ion Date of U y/Year) Sec		d Amount ying nd 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Owner Form Derive Securi Direct or Ind (s) (I)	of tive ty: (D)	(Instr. 4)
				Code	V	(A)	(D)	Date Exer	e rcisable	Expir Date	ation	Title	Amount or Number of Shares		(Instr. 4)	(Instr.	4)	
Restricted stock unit	\$ 0 (1)	04/04/2015		М			33,333		(1)	(	1)	Commo Stock	n 33,333	\$ 0 (1)	66,667	D		

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SNYDER STEPHEN ANDREW 7 CLYDE ROAD SOMERSET, NJ 08873	X		President			

#### **Signatures**

/s/ Amritpal Deol Attorney-in-Fact	11/06/2015
Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the conversion upon vesting of restricted stock units into common stock on April 4, 2015. These restricted stock units were acquired under the Company's 2014 Equity Incentive Plan, without payment by the reporting person. The remainder of the restricted stock units vests equally on April 4, 2016 and April 4, 2017.
- (2) Shares withheld by the issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
- The initial price of the Company's Series A, 11% Cumulative, Non-Convertible, Redeemable Perpetual Preferred Stock (the "Series A Preferred Stock") is \$25.00 per share. The Series
- (3) A Preferred Stock has no expiration date and is subject to all of the rights and obligations set forth in the Company's amended and restated certificate of incorporation, certificate of designations of the Series A Preferred Stock, and amended and restated bylaws.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Amritpal K. Deol, General Counsel and Corporate Secretary and Norman Roth, Controller, or either of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Medical Transcription Billing, Corp. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this  $\dot{\theta}^h$  day of November, 2015.

/s/ Stephen A. Snyder
Signature
Stephen A. Snyder
Print Name